PDL BioPharma (PDLI -5.3%) slips after Credit Suisse cut the shares to Neutral on valuation and...

|About: PDL BioPharma, Inc. (PDLI)|By:, SA News Editor

PDL BioPharma (PDLI -5.3%) slips after Credit Suisse cut the shares to Neutral on valuation and lowers its price target from $6.50 to $6.00. The firm adds that PDLI lacks significant optionality as new products deliver a finite and relatively short revenue stream.